The world's 24 best-selling prescription drugs in 2019

This article gives small partners a new list of the world's top 24 best-selling prescription drugs in 2019, covering several pharmaceutical companies, including Roche, Bayer and Pfizer, with annual sales of more than $4 billionthis list prepared by Yongjiang, a senior pharmaceutical industry analyst in Japan, for more than 20 years in a row to multinational pharmaceutical companies and global drug sales ranking, the past year from January to December of the year to the annual sales of heavy prescription drugs, if a drug by a number of companies jointly promote, then the cumulative sales calculation, through the past list, you can find these heavyweight brand drug market changesbelow is the list of the world's top 24 prescription drugs for 2019, each with sales of more than $4 billion in the past year:Compared to the 2013 list, total sales increased from $139 billion in 2013 to $175 billion last year, and the number one has been "drug king" Sioe, which, despite declining revenues from the impact of biosimilars in the European market, maintained sales of nearly $20 billion in 2019, and comparable autoimmune agents Eindy and Care not only sourcin, roche products, excluding Anvitin, were hit by a decline in sales in 2013the number of more than $4 billion increased by only two in 2019, but the number of varieties over $8 billion increased from five in 2013 to eightbiologics continue to take a larger share of the market, increasing from 10 to 14 compared to the 2013 list, so to speak, today's multinational pharmaceutical companies will be largely constrained by sales growth without biologicsthe 24 best-selling drugs in the world in 2019, the highest number of anti-tumor drugs, reached nine, followed by autoimmune drugs, four when Starnon is included, followed by anti-HIV drugs and multiple sclerosis drugs, with two eachin the 2013 list, there are 11 slow-onset drugs that sell more than $4 billion a year, such as the buck drug Novartis, GSK's Schulydy, Bollinger Ingerheim's Silihua, and the fat-lowering drug AstraZeneca' in 2019The under-diabetes drugs Genovy and insulin and sharp, even with the anticoagulant al-Elto, Bereto, and the new diabetes drug Easy, a total of only 5, and the Genovi market is still shrinking, in the list of these slow-disease drugs, can still maintain growth is easy to reach, the market for slow-disease heavy drugs have not much expectation.